Breaking News: A Class Action Lawsuit Against Regeneron Pharmaceuticals
Los Angeles, CA – March 7, 2025
Investors who have been following the biopharmaceutical industry may have recently come across some buzzing news. The Schall Law Firm, a leading national shareholder rights litigation firm, has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (Regeneron or the Company) for alleged securities law violations.
The Allegations
The lawsuit, filed on behalf of all persons or entities that purchased or otherwise acquired Regeneron securities between November 2, 2023, and October 30, 2024, inclusive (the Class Period), accuses the Company of violating ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Alleged Misrepresentations
The complaint asserts that Regeneron made false and misleading statements and failed to disclose material information during the Class Period, specifically regarding the safety and efficacy of its drugs, including EYLEA and Dupixent. These drugs were marketed as having minimal side effects and superior efficacy compared to competitors. However, it was later revealed that the drugs carried significant risks, such as potential vision loss and cardiovascular adverse events.
Impact on Regeneron and the Industry
The lawsuit could have far-reaching consequences for Regeneron and the biopharmaceutical industry as a whole. If the allegations are proven true, the Company may face significant financial penalties, including damages and fines. Moreover, the lawsuit could potentially tarnish Regeneron’s reputation, impacting investor confidence and sales.
Impact on Individual Investors
For individual investors, the lawsuit could result in financial losses if they purchased Regeneron securities during the Class Period. The lawsuit encourages these investors to contact The Schall Law Firm before March 10, 2025, to discuss their legal rights and potential remedies.
Future Developments
As the lawsuit progresses, it will be essential for investors to stay informed about any new developments. This includes regulatory actions, settlements, and court rulings. Keeping an eye on Regeneron’s financial performance and public statements will also be crucial.
Conclusion
The class action lawsuit against Regeneron Pharmaceuticals is a significant development for the biopharmaceutical industry and its investors. As the case unfolds, it’s essential for investors to stay informed and seek professional advice if they believe they may be affected. Only time will tell how this lawsuit will impact Regeneron and the industry as a whole.
- Regeneron Pharmaceuticals faces a class action lawsuit for securities law violations
- The lawsuit alleges false and misleading statements regarding the safety and efficacy of EYLEA and Dupixent
- Individual investors who purchased Regeneron securities during the Class Period may be affected
- The lawsuit could result in significant financial penalties for Regeneron
- Staying informed and seeking professional advice is crucial for investors
